Premium
BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)
Author(s) -
Bartlett N. L.,
Yasenchak C. A.,
Ashraf K. K.,
Harwin W. N.,
Sims R. B.,
Nowakowski G. S.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.166_2880
Subject(s) - lenalidomide , medicine , rituximab , brentuximab vedotin , oncology , phases of clinical research , placebo , diffuse large b cell lymphoma , lymphoma , clinical trial , gastroenterology , surgery , cd30 , multiple myeloma , pathology , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom